Poster sessions to highlight Phase 1 trials of
internal oncology candidates ZL-1310, a next-generation
antibody-drug conjugate for small cell lung cancer and other DLL3+
solid tumors, and ZL-1218, an anti-CCR8 antibody for advanced solid
tumors
These internally discovered programs underscore
the Company’s focus on extending oncology R&D innovation to
people with cancer worldwide
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that
two poster presentations highlighting ongoing global clinical
studies in its oncology pipeline will be presented at the upcoming
American Association for Cancer Research (AACR) Annual Meeting 2024
taking place April 5-10, 2024, in San Diego, California.
The global oncology programs to be showcased at AACR 2024
include a Phase 1a/1b study of ZL-1310 (NCT06179069), a novel
antibody-drug conjugate (ADC) within the Zai Lab pipeline that
targets the Delta-like ligand 3 (DLL3), a validated therapeutic
target for the treatment of small cell lung cancer (SCLC). ZL-1310
is designed with a novel linker-payload platform TMALIN® which
leverages the tumor microenvironment to overcome challenges
associated with first-generation ADC therapies.
Also featured at AACR 2024 will be Zai Lab’s Phase 1 study
(NCT05859464) of ZL-1218, an anti-CCR8 antibody that blocks
regulatory T cells (Treg) which suppress antitumor immunity in
tumor tissue and is designed to deplete Treg cells selectively in
tumors and minimally in other tissue.
“These ongoing global clinical studies underscore Zai Lab’s
continued commitment to pursue both novel and validated cancer
biology targets and advance innovative oncology therapies that can
potentially reach patients around the world,” said Rafael G. Amado,
M.D., President, Head of Global Oncology Research and Development,
Zai Lab. “We are dedicated to advancing the pipeline through both
drug discovery and partnerships to address therapeutic challenges
and unmet patient needs. As we extend the impact of our R&D
innovation on a global scale, we look forward to highlighting these
programs from our differentiated oncology pipeline at AACR
2024.”
Details regarding the Zai Lab poster presentations at AACR
2024 are as follows:
Title: Trial in Progress: A Phase 1a/1b, An Open-label,
Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability,
and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Presenter: Linda Liu, Ph.D., Senior Vice President,
Biologics Discovery, Zai Lab Session: PO.CTP01.02 - Phase I
Clinical Trials in Progress 2, CT155 / 6 Date/Time: Monday,
April 8, 2024, 1:30 PM - 5:00 PM PT Location: San Diego
Convention Center
Title: Trial in Progress: A Phase I, Open-label,
Multicenter Study of ZL-1218, an anti-CCR8 IgG1, as a Single Agent
and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the
Safety, Tolerability, and Pharmacokinetics in Subjects with
Advanced Solid Tumor Presenter: Maria Tea, M.D., Senior
Medical Director, Zai Lab Session: PO.CTP01.02 - Phase I
Clinical Trials in Progress 2, CT162 / 13 Date/Time: Monday,
April 8, 2024, 1:30 PM - 5:00 PM PT Location: San Diego
Convention Center
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative,
research-based, commercial-stage biopharmaceutical company based in
China and the United States. We are focused on discovering,
developing, and commercializing innovative products that address
medical conditions with significant unmet needs in the areas of
oncology, autoimmune disorders, infectious diseases and
neuroscience. Our goal is to leverage our competencies and
resources to positively impact human health in China and
worldwide.
For additional information about Zai Lab, please visit
www.zailaboratory.com or follow us at
www.twitter.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements relating
to our future expectations, plans, and prospects, for Zai Lab,
including, without limitation, statements relating to our prospects
and plans for developing and commercializing product candidates in
our oncology pipeline, including ZL-1310 and ZL-1218 and the
progress of related clinical trials, the potential benefits of
ZL-1310 and ZL-1218, and the potential treatment of SCLC and other
solid tumors. These forward-looking statements may contain words
such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,”
“potential,” “will,” “would,” and other similar expressions. Such
statements constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are not statements of historical fact or
guarantees or assurances of future performance. Forward-looking
statements are based on our expectations and assumptions as of the
date of this press release and are subject to inherent
uncertainties, risks, and changes in circumstances that may differ
materially from those contemplated by the forward-looking
statements. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including but not limited to (1) our ability to
successfully commercialize and generate revenue from our approved
products, (2) our ability to obtain funding for our operations and
business initiatives, (3) the results of our clinical and
pre-clinical development of our product candidates, (4) the content
and timing of decisions made by the relevant regulatory authorities
regarding regulatory approvals of our product candidates, (5) risks
related to doing business in China, and (6) other factors
identified in our most recent annual and quarterly reports and in
other reports we have filed with the U.S. Securities and Exchange
Commission (SEC). We anticipate that subsequent events and
developments will cause our expectations and assumptions to change,
and we undertake no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as may be required by law.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Our SEC filings can be found on our website at
www.zailaboratory.com and on the SEC’s website at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402667265/en/
For more information, please
contact: Investor Relations: Christine Chiou /
Lina Zhang +1 (917) 886-6929 / +86 136 8257 6943
christine.chiou1@zailaboratory.com /
lina.zhang@zailaboratory.com
Media: Jennifer Chang / Xiaoyu Chen +1 (857) 270-8985 /
+86 185 0015 5011 jennifer.chang@zailaboratory.com /
xiaoyu.chen@zailaboratory.com
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From Aug 2023 to Aug 2024